News|Articles|August 16, 2024

Gene therapy providing hope for patients diagnosed with inherited retinal diseases

Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.

A long-term review of voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics) has demonstrated that the treatment has resulted in long-term improvements in vision with patients diagnosed with biallelic RPE65 mutation-associated retinal diseases.